Curis, Inc. (NASDAQ: CRIS), a drug development company, is focused on utilizing its innovative signaling pathway drug technologies to discover new targeting small molecule drug candidates for cancer. Through the expansion of its drug development efforts in the field of cancer, the company is building upon its previous experiences in targeting signaling pathways to develop next generation targeted cancer therapies. For further information, visit the Company’s web site at www.curis.com.
- 17 years ago
QualityStocks
Curis, Inc. (NASDAQ: CRIS)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Highlights 2025 Pipeline Progress and Strategic Focus in Shareholder Letter
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company developing systemic oncolytic targeted immunotherapies, released…
-
QualityStocksNewsBreaks – Adageis Brings Key Advantages in Pivot to Value-Based Healthcare
Adageis offers providers tools that simplify operations and improve financial performance as healthcare shifts further toward…
-
QualityStocksNewsBreaks – Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) Advancing Strategic Path in Resurging Market
Platinum Group Metals (NYSE American: PLG) (TSX: PTM) is well positioned as platinum and palladium prices…